Summit Therapeutics on the rise after clinical results

0 mins. to read
Summit Therapeutics on the rise after clinical results
Master Investor Magazine

Master Investor Magazine 54Never miss an issue of Master Investor Magazine – sign-up now for free!

Read the latest Master Investor Magazine

AIM-listed pharmaceutical business Summit Therapeutics (LON:SUMM) has seen its share price rise by 9.80% to 28p (as of 15:30 BST) after its Ridinilazole treatment was found to improve short and longer term quality of life measurements for patients with C. difficile infections. The results from a phase 2 clinical trial were presented at a conference in Washington this month.

Chief Commercial Officer Dr. David Elger commented: “The patient is at the centre of our drug development universe. Global regulatory authorities and payors recognise that the value of treatments encompasses more than just clinical results and are placing increasing importance on patient reported outcomes, such as the EQ-5D index, in assessing new therapies. We are highly encouraged by the early and significant changes seen in the Phase 2 trial for patients on ridinilazole compared to the current standard of care, vancomycin, and look forward to the data from patient reported outcomes in our ongoing Phase 3 clinical trials of ridinilazole“.

Take part in our poll

Of the stocks covered by Master Investor in the weekly Small Cap Round Up, which ones do you hold?

The Master Investor Show 2020 tickets are now available. Join us at the Business Design Centre on Saturday 28 March 2020.

Book your FREE tickets today using code: MIBLOG

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *


Get real investment insights from some of the best minds in the business - with our free Master Investor Magazine.